Your Article Summary
See Latest ArticlesPharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest
The European Journal of Contraception & Reproductive Health Care, 06/30/09
Zeun S et al. - Treatment with an OC containing E2V and DNG was well tolerated and was associated with stable E2 concentrations over 28 days. The pharmacokinetics of DNG were consistent with previous findings. Minimum serum concentrations of DNG increased only slightly during phases of the regimen during which DNG was administered.
Related Articles
A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis
International Journal of Gynecology & Obstetrics, 10/13/09
Relevance Score: 83%
Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
Contraception, 10/16/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
International Journal of Women's Health, 12/18/09
Dienogest: a new therapeutic agent for the treatment of endometriosis
Women's Health, 12/17/09
Association of high-dose bifonazole administration during early pregnancy and severe limb reduction defects in the newborn
Birth Defects Research, 12/17/09
Today in Preventive Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Maternal and newborn morbidity by birth facility among selected United States 2006 low-risk births
American Journal of Obstetrics and Gynecology, 12/17/09
Retroperitoneal haematomas in obstetrics: literature review
Archives of Gynecology and Obstetrics, 12/17/09
Timing of Group B Streptococcus Screening in Pregnancy
Gynecologic and Obstetric Investigation, 12/17/09